Statins inhibit human APC function: implications for the treatment of GVHD.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

1. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
   Trial
2. Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
   Trial
3. Do Statins Affect Viral Infections Encountered by International Travelers?Tropical medicine and infectious disease · 2025
   Review
4. Fluvastatin Promotes Treg Cell Production in Allogeneic Immune Reaction and Suppresses Inflammatory Response.Immunity, inflammation and disease · 2025
   Article
5. Impact of Donor Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2023
   Observational
6. From support to therapy: rethinking the role of nutrition in acute graft-versus-host disease.Frontiers in immunology · 2023
   Review
7. Effect of Statins on the Risk of Poststroke Pneumonia: National Population-Based Cohort Study.Infection and drug resistance · 2020
   Article
8. Correlation of T Cell Subsets and Hypercholesterolemia of the Donor and Its Association with Acute Graft-versus-Host Disease.International journal of hematology-oncology and stem cell research · 2019
   Article
9. Immune modulatory effects of statins.Immunology · 2018
   Review
10. Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease.Current pathobiology reports · 2018
    Review
11. Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis.Regenerative engineering and translational medicine · 2016
    Article
12. Current and emerging strategies for the prevention of graft-versus-host disease.Nature reviews. Clinical oncology · 2014
    Review
13. Overcoming immunological barriers in regenerative medicine.Nature biotechnology · 2014
    Article
14. Prevention of graft-vs.-host disease.Expert opinion on pharmacotherapy · 2012
    Review
15. The evolving role of statins in hematopoietic stem and progenitor cell transplantation.American journal of blood research · 2011
    Article
16. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2010
    Article
17. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.Blood · 2010
    Article
18. Statins impair CD1d-mediated antigen presentation through the inhibition of prenylation.Journal of immunology (Baltimore, Md. : 1950) · 2009
    Article
19. Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs.Journal of immunotherapy (Hagerstown, Md. : 1997)
    Article

Corrections and comments

• Comment on
  Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.2007

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as